• LAST PRICE
    1.8700
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.5376%)
  • Bid / Lots
    1.8700/ 1
  • Ask / Lots
    1.9200/ 1
  • Open / Previous Close
    1.9400 / 1.8600
  • Day Range
    Low 1.8700
    High 1.9400
  • 52 Week Range
    Low 1.6700
    High 8.1969
  • Volume
    26,507
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.86
TimeVolumeNOVN
09:32 ET12571.94
09:34 ET3581.9051
09:38 ET2311.925
10:12 ET8001.9
10:14 ET10601.9
10:17 ET5001.9076
10:19 ET1001.91
10:35 ET8361.91
10:44 ET10001.91
10:51 ET1011.905
10:53 ET1001.9
10:55 ET27141.9
11:15 ET1001.91
11:22 ET3001.91
11:29 ET2501.9064
12:12 ET1001.91
12:18 ET7851.92
01:44 ET1001.91
02:08 ET13101.9011
02:09 ET6851.9009
02:11 ET1131.9019
02:47 ET21901.88
02:49 ET1751.885
02:58 ET1501.8815
03:03 ET1001.8723
03:16 ET2501.88
03:38 ET1001.8727
03:39 ET1001.88
03:54 ET10001.8884
03:57 ET2621.8767
03:59 ET6781.87
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNOVN
Novan Inc
36.4M
-1.0x
---
United StatesNHWK
NightHawk Biosciences Inc
44.4M
-1.1x
---
United StatesHYEX
Healthy Extracts Inc
21.6M
-23.4x
---
United StatesCOCP
Cocrystal Pharma Inc
26.3M
-0.8x
---
United StatesSISI
Shineco Inc
13.3M
-0.2x
---
United StatesALID
Allied Corp
55.2M
-2.0x
---
As of 2022-10-01

Company Information

Novan, Inc.is a pre-commercial nitric oxide-based pharmaceutical company. The Company is engaged in researching, developing and marketing products for skin diseases. The Company is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The Company has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The Company is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

Contact Information

Headquarters
4020 Stirrup Creek Drive, Suite 110DURHAM, NC, United States 27703
Phone
919-485-8080
Fax
302-531-3150

Executives

Chairman of the Board, President, Chief Executive Officer
Paula Stafford
Chief Financial Officer, Principal Financial Officer, Corporate Secretary
John Gay
Chief Commercial Officer
Brian Johnson
Lead Independent Director
W. Kent Geer
Independent Director
James Bierman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$36.4M
Revenue (TTM)
$9.5M
Shares Outstanding
21.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.51
EPS
$-1.93
Book Value
$0.97
P/E Ratio
-1.0x
Price/Sales (TTM)
3.8
Price/Cash Flow (TTM)
---
Operating Margin
-380.74%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.